Maintenance therapy for lung cancer that turned small cell after EGFR treatment
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two combination maintenance drugs (a targeted pill and an anti-angiogenesis drug) for people whose non-small cell lung cancer has turned into small cell lung cancer after EGFR-targeted therapy. The goal is to see if this combination can help keep the cancer under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with non-small cell lung cancer that has spread or is advanced.
- After taking an EGFR-targeted pill (like osimertinib), your cancer must have stopped responding and a biopsy must show that part of it turned into small cell lung cancer.
- You should be in reasonably good health, with a performance score of 0 to 2 (0 = fully active, 2 = able to care for yourself but not work).
- You must not have had another cancer in the past 2 years, and no stroke or brain bleeding in the past 6 months.
- You must not have uncontrolled infections, heart problems, or lung scarring, and must be able to swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy (limertinib) combined with standard chemotherapy (carboplatin and etoposide) for people whose EGFR-positive lung cancer has transformed into small cell lung cancer after failing an EGFR inhibitor. The goal is to see if this combination can slow the cancer and help you live longer.
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
This study tests a combination of two targeted therapies for non-small cell lung cancer that has continued to grow despite previous EGFR-targeted treatment. It aims to see if adding gumarontinib (a MET inhibitor) to another EGFR-targeted drug can control the cancer for longer.
This trial tests a new combination of two medications (SKB264 and anlotinib) for people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to a standard pill called an EGFR-TKI. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.